{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:47:08Z","timestamp":1759229228519},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,8,17]],"date-time":"2004-08-17T00:00:00Z","timestamp":1092700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Mater Res"],"published-print":{"date-parts":[[2005,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Wear debris\u2010induced osteolysis is the major cause of aseptic loosening and failure of hip implants. One of the promising therapeutic interventions to improve the longevity of hip implants is to administrate bisphosphonate drug to inhibit osteoclastic bone resorption. This study aimed at developing new techniques of directly combining bisphosphonate with implants to achieve local delivery and controlled release of the drug. Instead of using soluble sodium salt, we proposed to apply sparingly soluble calcium salt of bisphosphonate as a potential long\u2010term antiosteolysis coating on hip implants. Calcium salt of etidronate, a member of the bisphosphonate family of potent osteoclast inhibitors, was used in this pilot study. By adopting the electrolytic deposition (ELD) technique, which was developed for ceramic coatings including calcium phosphates, we demonstrated that a thin layer of calcium bisphosphonate could be deposited onto titanium surface. The drug coating is amorphous as characterized with X\u2010ray diffraction, and has globular morphology under the scanning electron microscope. Electrospray\u2010ionization mass\u2010spectrometry (ESI\u2010MS) and Fourier\u2010transformed infrared spectroscopy confirmed that the molecular structure of the etidronate (<jats:italic>m<\/jats:italic>\/<jats:italic>z<\/jats:italic> 205, H<jats:sub>3<\/jats:sub>L<jats:sup>\u2212<\/jats:sup>, the single dissociated form of parent etidronic acid, denoted as H<jats:sub>4<\/jats:sub>L) was preserved after the ELD process. <jats:italic>In vitro<\/jats:italic> release into a \u201cphysiological\u201d buffer solution confirmed that the etidronate concentration was limited by its low solubility. The etidronate concentration was 8 \u00d7 10<jats:sup>\u22125<\/jats:sup> <jats:italic>M<\/jats:italic> at day 1 and kept relatively stable at \u223c6 \u00d7 10<jats:sup>\u22125<\/jats:sup> <jats:italic>M<\/jats:italic> from day 2 to day 8. The deposition mechanisms of the drug coating and its potential efficacy as an antiosteolytic release source were discussed. \u00a9 2004 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 72B: 43\u201351, 2005<\/jats:p>","DOI":"10.1002\/jbm.b.30112","type":"journal-article","created":{"date-parts":[[2004,8,17]],"date-time":"2004-08-17T21:05:06Z","timestamp":1092776706000},"page":"43-51","source":"Crossref","is-referenced-by-count":14,"title":["Electrolytic deposition of calcium etidronate drug coating on titanium substrate"],"prefix":"10.1002","volume":"72B","author":[{"given":"Ke","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,8,17]]},"reference":[{"key":"e_1_2_6_2_2","series-title":"Total hip replacement consensus statement 1994","first-page":"1","author":"National Institute of Health","year":"1994"},{"key":"e_1_2_6_3_2","first-page":"3","article-title":"Implant wear in total joint replacement: Clinical and biologic issues, material and design considerations","author":"Wright TM","year":"2001","journal-title":"Am Acad Orthopaed Surg"},{"key":"e_1_2_6_4_2","first-page":"46","article-title":"The problem is osteolysis","volume":"311","author":"Harris WH","year":"1995","journal-title":"Clin Orthop"},{"key":"e_1_2_6_5_2","first-page":"1","volume-title":"Hip replacements: Current trends and controversies","author":"Muratoglu OK","year":"2002"},{"key":"e_1_2_6_6_2","volume-title":"Bisphosphonates in bone disease: From the laboratory to the patient","author":"Fleisch H","year":"2000"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.10.614"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.1100180602"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4636(199605)31:1<91::AID-JBM11>3.0.CO;2-P"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-199711000-00005"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.7.1300"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1902\/jop.1999.70.10.1228"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(01)00415-X"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1019892109411"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2000.71.2.272"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/la9603277"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/cm00012a001"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00735695"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-8686(01)00068-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2944(73)90100-2"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600770903"},{"key":"e_1_2_6_22_2","volume-title":"Interpretation of the infrered spectra of organophosphorous compounds","author":"Thomas LC","year":"1974"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-0728(98)00107-7"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-4931(02)00026-7"},{"key":"e_1_2_6_25_2","first-page":"204","article-title":"Pharmaceutical application of gas chromatography\u2010mass spectrometry. 2. Ion chromatography ion\u2010spray mass\u2010spectrometric characterization of alendronate","volume":"686","author":"Qing XZ","year":"1994","journal-title":"J Chromatogr A"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(99)01291-1"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-265X(84)90130-9"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/03639049509026665"},{"key":"e_1_2_6_29_2","first-page":"1001","article-title":"Slow\u2010release clodronate in prevention of inflammation and bone loss associated with adjuvant arthritis","volume":"280","author":"Osterman T","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(97)00270-6"},{"key":"e_1_2_6_31_2","first-page":"6001","article-title":"Bisphosphonates directly regulate cell proliferation, differentiation and gene expression in human osteoblasts","volume":"60","author":"Reinholz GG","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2003.11.024"}],"container-title":["Journal of Biomedical Materials Research Part B: Applied Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbm.b.30112","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbm.b.30112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T16:23:51Z","timestamp":1697127831000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jbm.b.30112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,17]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,15]]}},"alternative-id":["10.1002\/jbm.b.30112"],"URL":"https:\/\/doi.org\/10.1002\/jbm.b.30112","archive":["Portico"],"relation":{},"ISSN":["1552-4973","1552-4981"],"issn-type":[{"value":"1552-4973","type":"print"},{"value":"1552-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,17]]}}}